|
|
|
| Effect of Gongyankang granule combined with levofloxacin and ornidazole for treating patients with sequela of pelvic inflammatory diseases, and its influence on inflammatory factors and hemorheologyof patients |
| Shunyi District Hospital, Beijing, 101300 |
|
|
|
|
Abstract Objective: To investigate the effects of Gongyankang granule combined with levofloxacin and ornidazole for treating patients with sequela of pelvic inflammatory diseases (PID sequelae), and to study its influence on inflammatory factors and hemorheology of patients. Methods: 82 patients with sequelae of PID were randomly divided into the control group and the observation group (41 cases in each group) from January 2017 to February 2018. The patients in the control group were treated by levofloxacin and ornidazole, and the patients in the observation group was treated by Gongyankang granules combined with levofloxacin and ornidazole. The inflammatory factors levels and hemorheological changes of patients were evaluated before and after treatment, and the clinical efficacy and adverse reactions of patients were observed in both groups. Results: After treatment, the levels of TNF-α, hs-CRP and MCP-1, and the values of specific viscosity of low cut whole blood, the specific viscosity of high cut whole blood, and the specific viscosity of plasma of patients had significantly decreased, and those of patients in the observation group was significant lower than those of patients in the control group (P<0.05). The total clinical effective rate of patients in the observation group was 97.6%, which was significant higher than that (85.4%) of patients in the control group (P=0.048). There was no significant difference in the incidence of adverse reactions (9.8% Vs.14.6%) between the two groups (P=0.500). Conclusion: Gongyankang granule combined with levofloxacin and ornidazole can reduce the inflammatory response of patients with PID sequelae, improve hemorheology and clinical efficacy, which has good safety and clinical application value.
|
|
|
|
|
|
|
|
|
